Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experince.
Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson?s disease (PD). We had telephone calls with 44 patients from 11 neurology centers who were on LCIG treatment were included in an eight items survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intra-class correlation coefficient on every question separately. Average age of the patients were 63.48 and duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were `better? after LCIG treatment were: 80% for time spent in off, 55% for dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence, and 70% for activities of daily living. Cronbach?s alpha was 0.795 and also, intraclass correlation coefficient (ICC) was reliably for the items. As it is detected by a survey performed by telephone calls with good interrater reliability, patients with PD gets better with LCIG treatment in many aspects of the disease.